Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)

Diagnostics guidance DG10
Issued: September 2013

- early and locally advanced breast cancer pathway
  Fast, easy summary view of NICE guidance on 'early and locally advanced breast cancer'
- Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat
  Diagnostics guidance, DG10 - Issued: September 2013 NICE has assessed the MammaPrint, Oncotype DX, IHC4 and Mammostrat to help the NHS decide whether to use these products.
  MammaPrint, Oncotype DX, IHC4 and Mammostrat are tests for certain genes or proteins found in breast cancer tumours. Testing for the levels of these may give healthcare professionals an indication of how a tumour might develop, and therefore help in treatment planning.
  NICE has said that Oncotype DX is recommended to help make decisions about chemotherapy after surgery in some people with oestrogen receptor positive (ER+), lymph node negative (LN−) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer. Your healthcare professional should discuss with you whether this might be right for you.
  NICE has said that MammaPrint, IHC4 and Mammostrat should only be used in research. This is because it’s not certain how much benefit they can provide.
  - Other information
    NICE Pathways
    This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
    Visit the NICE Pathway: early and locally advanced breast cancer
    
    How this guidance was produced
    Background information
    - None found
  This page was last updated: 26 September 2013